Ind-Swift Labs.

{
  "main_header": {
    "sid": 393806,
    "name": "Ind-Swift Labs.",
    "stock_name": "Ind-Swift Labs.",
    "full_name": "Ind-Swift Laboratories Ltd",
    "name_url": "stocks-analysis/ind-swift-labs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "151.95",
    "chg": 17.1,
    "chgp": "12.68%",
    "dir": 1,
    "prev_price": "134.85",
    "mcapval": "1,381.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 532305,
    "symbol": "INDSWFTLAB",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE915B01019",
    "curr_date": "May 29",
    "curr_time": "",
    "bse_nse_vol": "78.02 lacs",
    "exc_status": "Active",
    "traded_date": "May 29, 2026",
    "traded_date_str": "2026 05 29",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ind-swift-labs-393806-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "text": "Part of MojoOne Strategy",
      "type": "MN",
      "url": "https://www.marketsmojo.com/mojopro/strategy/2",
      "ismore": 0,
      "all_data": [],
      "is_blur": 1,
      "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ind-swift-labs-393806-0&utm_source=Spage_Score_PartofStrategies"
    }
  },
  "news": {
    "results": [
      {
        "title": "Ind-Swift Laboratories Q4 FY26: Turnaround Gains Momentum as Profitability Returns",
        "link": "https://www.marketsmojo.com/news/result-analysis/ind-swift-laboratories-q4-fy26-turnaround-gains-momentum-as-profitability-returns-4022125",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/IndSwiftLaborat_quaterlyResult_4022125.png",
        "date": "2026-05-29 16:23:25",
        "description": "Ind-Swift Laboratories Ltd., a Chandigarh-based active pharmaceutical ingredients (API) manufacturer, reported a consolidated net profit of ₹15.11 crores for Q4 FY26 (Mar'26), marking a significant 58.39% quarter-on-quarter improvement from ₹9.54 crores in Q3 FY26 (Dec'25). However, on a year-on-year basis, the profit declined sharply by 93.20% from an exceptional ₹222.27 crores in Q4 FY25, which was inflated by extraordinary gains. The company's stock surged 12.68% to ₹151.95 following the results announcement, reflecting investor optimism about the operational turnaround."
      },
      {
        "title": "Broad-Based Technical Strength Lifts Ind-Swift Laboratories Ltd to 52-Week High of Rs 158.15",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ind-swift-laboratories-ltd-hits-new-52-week-high-at-rs15815-4019593",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/IndSwiftLaborat_priceRelatedfactors_4019593.png",
        "date": "2026-05-29 09:42:48",
        "description": "Surging past its previous peaks, Ind-Swift Laboratories Ltd touched a fresh 52-week high of Rs 158.15 on 29 May 2026, marking a remarkable rally that has more than doubled its share price from the low of Rs 77.09 recorded last year. This milestone underscores the stock’s strong price momentum amid a mixed broader market backdrop."
      },
      {
        "title": "Ind-Swift Laboratories Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ind-swift-laboratories-ltd-is-rated-sell-4000720",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/IndSwiftLaborat_mojoScore_4000720.png",
        "date": "2026-05-20 10:10:56",
        "description": "Ind-Swift Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 May 2026, providing investors with the latest insights into the company's performance and outlook."
      },
      {
        "title": "Ind-Swift Laboratories Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ind-swift-laboratories-ltd-is-rated-sell-3982766",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/IndSwiftLaborat_mojoScore_3982766.png",
        "date": "2026-05-09 10:10:25",
        "description": "Ind-Swift Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 May 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Ind-Swift Laboratories Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ind-swift-laboratories-ltd-is-rated-sell-3982757",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/IndSwiftLaborat_mojoScore_3982757.png",
        "date": "2026-05-09 10:10:25",
        "description": "Ind-Swift Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Ind-Swift Laboratories Downgraded to Sell Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ind-swift-laboratories-downgraded-to-sell-amid-mixed-financial-and-technical-signals-3965854",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/IndSwiftLaborat_mojoScore_3965854.png",
        "date": "2026-04-28 08:22:35",
        "description": "Ind-Swift Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 27 April 2026. This change reflects a complex interplay of deteriorating financial fundamentals, cautious valuation metrics, and a shift in technical indicators, despite the company’s strong recent stock performance and positive quarterly results."
      },
      {
        "title": "Ind-Swift Laboratories Gains 3.98%: 4 Key Factors Driving the Week",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ind-swift-laboratories-gains-398-4-key-factors-driving-the-week-3962819",
        "imagepath": "",
        "date": "2026-04-25 17:10:30",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>20 Apr:</strong> Downgrade to Sell amid mixed financial signals</p>\n                    <p><strong>22 Apr:</strong> Bullish momentum observed despite mixed technical indicators</p>\n                    <p><strong>23 Apr:</strong> Upgrade to Hold following technical and financial improvements</p>\n                    <p><strong>24 Apr:</strong> Technical momentum shifts to mildly bullish amid mixed signals</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.132.10</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><di..."
      },
      {
        "title": "Ind-Swift Laboratories Ltd: Technical Momentum Shifts Amid Mixed Indicator Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ind-swift-laboratories-ltd-technical-momentum-shifts-amid-mixed-indicator-signals-3960053",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/IndSwiftLaborat_technicaldot_3960053.png",
        "date": "2026-04-24 08:00:56",
        "description": "Ind-Swift Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflected in a complex interplay of bullish and bearish signals across key indicators. Despite a recent downgrade in daily price performance, the stock’s longer-term metrics suggest a cautiously optimistic outlook, prompting a reassessment of its technical stance from Sell to Hold."
      },
      {
        "title": "Ind-Swift Laboratories Ltd Upgraded to Hold on Technical and Financial Improvements",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ind-swift-laboratories-ltd-upgraded-to-hold-on-technical-and-financial-improvements-3958548",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/IndSwiftLaborat_mojoScore_3958548.png",
        "date": "2026-04-23 08:11:00",
        "description": "Ind-Swift Laboratories Ltd has seen its investment rating upgraded from Sell to Hold, driven primarily by a marked improvement in technical indicators and encouraging quarterly financial results. Despite lingering concerns over long-term fundamentals and profitability, the stock’s recent performance and technical outlook have prompted a reassessment of its market stance."
      }
    ],
    "total": 193,
    "sid": "393806",
    "stock_news_url": "https://www.marketsmojo.com/news/ind-swift-laboratories-393806"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Meeting To Be Held On May 28 2026.",
      "datetime": "22-May-2026",
      "details": "Ind-Swift Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 inter alia to consider and approve and take on record Standalone and Consolidated Audited Financial Results for the Quarter and Financial Year ended March 31 2026.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Monitoring Agency Report",
      "datetime": "15-May-2026",
      "details": "Please find enclosed report of the Monitoring Agency for the quarter ended March 31 2026.",
      "source": "BSE"
    },
    {
      "caption": "Shareholder Meeting / Postal Ballot-Scrutinizers Report",
      "datetime": "05-May-2026",
      "details": "Please find attached Scrutinizers Report along with Voting Results for the resolutions passed through postal ballot on 30.04.2026.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Ind-Swift Laboratories Ltd has declared <strong>10%</strong> dividend, ex-date: 20 Sep 11",
          "dt": "2011-09-20",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Ind-Swift Laboratories Q4 FY26: Turnaround Gains Momentum as Profitability Returns

2026-05-29 16:23:25

Ind-Swift Laboratories Ltd., a Chandigarh-based active pharmaceutical ingredients (API) manufacturer, reported a consolidated net profit of ₹15.11 crores for Q4 FY26 (Mar'26), marking a significant 58.39% quarter-on-quarter improvement from ₹9.54 crores in Q3 FY26 (Dec'25). However, on a year-on-year basis, the profit declined sharply by 93.20% from an exceptional ₹222.27 crores in Q4 FY25, which was inflated by extraordinary gains. The company's stock surged 12.68% to ₹151.95 following the results announcement, reflecting investor optimism about the operational turnaround.

Read full news article

Broad-Based Technical Strength Lifts Ind-Swift Laboratories Ltd to 52-Week High of Rs 158.15

2026-05-29 09:42:48

Surging past its previous peaks, Ind-Swift Laboratories Ltd touched a fresh 52-week high of Rs 158.15 on 29 May 2026, marking a remarkable rally that has more than doubled its share price from the low of Rs 77.09 recorded last year. This milestone underscores the stock’s strong price momentum amid a mixed broader market backdrop.

Read full news article

Ind-Swift Laboratories Ltd is Rated Sell

2026-05-20 10:10:56

Ind-Swift Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 May 2026, providing investors with the latest insights into the company's performance and outlook.

Read full news article

Ind-Swift Laboratories Ltd is Rated Sell

2026-05-09 10:10:25

Ind-Swift Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Ind-Swift Laboratories Ltd is Rated Sell

2026-05-09 10:10:25

Ind-Swift Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Ind-Swift Laboratories Downgraded to Sell Amid Mixed Financial and Technical Signals

2026-04-28 08:22:35

Ind-Swift Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 27 April 2026. This change reflects a complex interplay of deteriorating financial fundamentals, cautious valuation metrics, and a shift in technical indicators, despite the company’s strong recent stock performance and positive quarterly results.

Read full news article

Ind-Swift Laboratories Gains 3.98%: 4 Key Factors Driving the Week

2026-04-25 17:10:30

Key Events This Week

20 Apr: Downgrade to Sell amid mixed financial signals

22 Apr: Bullish momentum observed despite mixed technical indicators

23 Apr: Upgrade to Hold following technical and financial improvements

24 Apr: Technical momentum shifts to mildly bullish amid mixed signals

Week Open

Rs.132.10

Week Close

Read full news article

Ind-Swift Laboratories Ltd: Technical Momentum Shifts Amid Mixed Indicator Signals

2026-04-24 08:00:56

Ind-Swift Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflected in a complex interplay of bullish and bearish signals across key indicators. Despite a recent downgrade in daily price performance, the stock’s longer-term metrics suggest a cautiously optimistic outlook, prompting a reassessment of its technical stance from Sell to Hold.

Read full news article

Ind-Swift Laboratories Ltd Upgraded to Hold on Technical and Financial Improvements

2026-04-23 08:11:00

Ind-Swift Laboratories Ltd has seen its investment rating upgraded from Sell to Hold, driven primarily by a marked improvement in technical indicators and encouraging quarterly financial results. Despite lingering concerns over long-term fundamentals and profitability, the stock’s recent performance and technical outlook have prompted a reassessment of its market stance.

Read full news article

View All News